We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Nimbus Thinks It Has “Non-First-Mover” Advantage In NASH

This article was originally published in The Pink Sheet Daily

20 Mar 2015

News

Executive Summary

Working on an allosteric ACC inhibitor in NASH, Nimbus is not worried about being first to market but is willing to let others develop and prove out a pivotal development pathway in the indication, while it focuses on a unique mechanism of action.